U.S. FDA approves Stemline Therapeutics’ rare blood disease treatment

The U.S. Food and Drug Administration on Friday approved Stemline Therapeutics Inc’s Elzonris for the treatment of a rare blood disease in adults and children aged two years and above.

Original source: http://feeds.reuters.com/~r/reuters/INhealth/~3/bTfMKEmzAF4/u-s-fda-approves-stemline-therapeutics-rare-blood-disease-treatment-idINKCN1OK1SQ

Related Posts